486 related articles for article (PubMed ID: 31481441)
1. Therapeutic Challenges of Non-
Lamoth F; Kontoyiannis DP
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481441
[TBL] [Abstract][Full Text] [Related]
2. Changes in the epidemiological landscape of invasive mould infections and disease.
Lass-Flörl C; Cuenca-Estrella M
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462
[TBL] [Abstract][Full Text] [Related]
3. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.
Jenks JD; Reed SL; Seidel D; Koehler P; Cornely OA; Mehta SR; Hoenigl M
Int J Antimicrob Agents; 2018 Nov; 52(5):706-712. PubMed ID: 30099056
[TBL] [Abstract][Full Text] [Related]
4. Non-Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive Mycoses.
Jacobs SE; Wengenack NL; Walsh TJ
Semin Respir Crit Care Med; 2020 Feb; 41(1):115-130. PubMed ID: 32000288
[TBL] [Abstract][Full Text] [Related]
5. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
Lortholary O; Fernández-Ruiz M; Perfect JR
J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
[TBL] [Abstract][Full Text] [Related]
6. Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis.
Alkhazraji S; Gebremariam T; Alqarihi A; Gu Y; Mamouei Z; Singh S; Wiederhold NP; Shaw KJ; Ibrahim AS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818813
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope
Seidel D; Meißner A; Lackner M; Piepenbrock E; Salmanton-García J; Stecher M; Mellinghoff S; Hamprecht A; Durán Graeff L; Köhler P; Cheng MP; Denis J; Chedotal I; Chander J; Pakstis DL; Los-Arcos I; Slavin M; Montagna MT; Caggiano G; Mares M; Trauth J; Aurbach U; Vehreschild MJGT; Vehreschild JJ; Duarte RF; Herbrecht R; Wisplinghoff H; Cornely OA
Crit Rev Microbiol; 2019 Feb; 45(1):1-21. PubMed ID: 30628529
[TBL] [Abstract][Full Text] [Related]
8. Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.
Lamoth F; Damonti L; Alexander BD
J Clin Microbiol; 2016 Jun; 54(6):1638-1640. PubMed ID: 27008871
[TBL] [Abstract][Full Text] [Related]
9. Invasive mould infections in the ICU setting: complexities and solutions.
Bassetti M; Bouza E
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466
[TBL] [Abstract][Full Text] [Related]
10. Emergence of the Molds Other than Aspergillus in Immunocompromised Patients.
Arif S; Perfect JR
Clin Chest Med; 2017 Sep; 38(3):555-573. PubMed ID: 28797495
[TBL] [Abstract][Full Text] [Related]
11. Challenges in management of invasive fungal infections in stem cell transplant.
Walker J; Edwards WS; Hall NM; Pappas PG
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14175. PubMed ID: 37864814
[TBL] [Abstract][Full Text] [Related]
12. [State of the art in invasive diseases by filamentous fungi].
Pemán J; Quindós G
Rev Iberoam Micol; 2014; 31(4):213-8. PubMed ID: 25449676
[TBL] [Abstract][Full Text] [Related]
13. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
[TBL] [Abstract][Full Text] [Related]
14. Detection of the 'Big Five' mold killers of humans: Aspergillus, Fusarium, Lomentospora, Scedosporium and Mucormycetes.
Thornton CR
Adv Appl Microbiol; 2020; 110():1-61. PubMed ID: 32386603
[TBL] [Abstract][Full Text] [Related]
15. Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021.
Bupha-Intr O; Butters C; Reynolds G; Kennedy K; Meyer W; Patil S; Bryant P; Morrissey CO;
Intern Med J; 2021 Nov; 51 Suppl 7():177-219. PubMed ID: 34937139
[TBL] [Abstract][Full Text] [Related]
16. Practical issues related to non-Aspergillus invasive mold infections.
Nucci M; Nouér SA
Mol Aspects Med; 2023 Dec; 94():101230. PubMed ID: 38011770
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN; Carver PL
Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
[TBL] [Abstract][Full Text] [Related]
18. PCR diagnostic platforms for non-
Lamoth F; Kontoyiannis DP
Expert Rev Mol Diagn; 2024 Apr; 24(4):273-282. PubMed ID: 38501431
[TBL] [Abstract][Full Text] [Related]
19. Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.
Neoh CF; Chen SC; Lanternier F; Tio SY; Halliday CL; Kidd SE; Kong DCM; Meyer W; Hoenigl M; Slavin MA
Clin Microbiol Rev; 2024 Jun; 37(2):e0000423. PubMed ID: 38551323
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients.
Peghin M; Monforte V; Martin-Gomez MT; Ruiz-Camps I; Berastegui C; Saez B; Riera J; Solé J; Gavaldá J; Roman A
Transpl Infect Dis; 2016 Feb; 18(1):70-8. PubMed ID: 26678668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
